Zoetis

Zoetis Stock-Based Compensation

The Stock-Based Compensation (SBC) of Zoetis (ZTS) as of Oct 28, 2026 is 83.00 M USD. In the previous year, Stock-Based Compensation (SBC) was 74.00 M USD — a change of 12.16% (higher).

Stock-Based Compensation

83.00 MUSD

YoY

12.16%

Last updated:

Stock-Based Compensation (SBC) of Zoetis is 2025 83.00 M USD. Stock-Based Compensation (SBC) of Zoetis was 2024 74.00 M USD. It decreases by 12.16% higher compared to the previous year.

The Zoetis Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
53.00 M USD
Jan 1, 2019
67.00 M USD
Jan 1, 2020
59.00 M USD
Jan 1, 2021
58.00 M USD
Jan 1, 2022
62.00 M USD
Jan 1, 2023
60.00 M USD
Jan 1, 2024
74.00 M USD
Jan 1, 2025
83.00 M USD
The Zoetis Stock-Based Compensation history
YEARStock-Based CompensationYoY
83.00 MUSD+12.16%
74.00 MUSD+23.33%
60.00 MUSD-3.23%
62.00 MUSD+6.90%
58.00 MUSD-1.69%
59.00 MUSD-11.94%
67.00 MUSD+26.42%
53.00 MUSD+20.45%
44.00 MUSD+18.92%
37.00 MUSD-13.95%
43.00 MUSD+34.38%
32.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zoetis Stock analysis

What does Zoetis do? Zoetis Inc. is a leading company in the development and marketing of animal health technology and solutions. The company specializes in innovative products for animals such as dairy cattle, pigs, poultry, dogs, cats, and horses. Zoetis was founded in 1952 as a subsidiary of Pfizer and operated as Pfizer Animal Health. In 2013, the company was finally spun off from Pfizer and became Zoetis Inc. Zoetis focuses on the development, manufacturing, and marketing of products for livestock and pets, including vaccines, pharmaceuticals, biological therapies, and diagnostics. The company operates globally and has its headquarters in Parsippany, New Jersey. Zoetis' business model consists of various business segments divided into animal categories: cattle, pigs, poultry, pets, and horses. Each of these business segments offers specialized solutions for animal owners and veterinarians. In the cattle products segment, Zoetis offers products for dairy cows, beef cattle, and calves. They also provide a variety of prevention and treatment solutions for major animal health issues such as mastitis, reproductive disorders, and respiratory problems. In the swine segment, Zoetis offers prevention and treatment solutions for infectious diseases and parasite control. They also provide products for promoting swine health and weight gain. In the poultry segment, Zoetis offers solutions for the prevention and treatment of infectious diseases. The company's products aim to improve animal health, productivity, and efficiency. Zoetis also offers products for the pet segment, including vaccines, pharmaceuticals, and therapies for dogs, cats, and other pets. Here, the company also provides solutions for major health issues such as heart diseases, pain management, and parasite control. In the horse segment, Zoetis offers solutions for the prevention and treatment of diseases such as equine rhinopneumonia, worm infestations, and arthritis. They also provide products for promoting horse health and performance. Zoetis is known for a variety of innovative products used by animal owners and veterinarians worldwide. One example is ScourGuard® 4KC, a vaccine that protects calves from diarrheal diseases caused by common bacteria. This vaccine has already proven to be highly effective in controlling bowel diseases in calves. Zoetis has also developed and marketed the first FDA-approved product for pain management in dogs (Rimadyl®), as well as the first licensed product for the treatment of giardia in dogs (Panacur®). In summary, Zoetis, as a global leader in the animal health industry, puts innovation and quality at the forefront. With a wide range of products and solutions in various animal categories, Zoetis is a key player in the animal health industry. Zoetis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zoetis stock

Stock-Based Compensation (SBC) of Zoetis is 83.00 M USD in 2025.

Stock-Based Compensation (SBC) of Zoetis changed from 74.00 M USD to 83.00 M USD, representing a 12.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Zoetis since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Zoetis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zoetis

All Key Metrics — Zoetis